INO — Inovio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $92.76m
- $56.08m
- $0.07m
U.S. STOCKS ON THE MOVE-Kodiak Sciences, Intensity Therapeutics, Inovio Pharma
U.S. STOCKS ON THE MOVE-Kodiak Sciences, Intensity Therapeutics, Inovio Pharma
Inovio Pharma rises on FDA's 'breakthrough' tag for respiratory disease therapy
Brief: Inovio Announces U.S. FDA Breakthrough Therapy Designation Granted For Ino-3107 For The Treatment Of Recurrent Respiratory Papillomatosis
Precigen gains as Stifel raises PT on company's lead therapy prospects
Inovio Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Inovio Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Inovio Pharmaceuticals Says On July 31, Committed To, Communicated A Corporate Reorganization Plan
Inovio Pharma rises on EU's 'orphan tag' for respiratory disease therapy
Brief: Inovio Announces Orphan Drug Designation For INO-3107 From European Commission
U.S. RESEARCH ROUNDUP-Allakos, Virtu Financial, Walt Disney
Inovio Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Inovio Reports First Quarter 2023 Financial Results And Operational Highlights
Inovio Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: European Committee For Orphan Medicinal Products Provides Positive Opinion On Inovio's Application For Orphan Drug Designation For Ino-3107
Brief: Data From Phase 1B Trial With Ino-4201 As An Ebola Booster For Rvsv-Zebov (Ervebo®) Presented At Eccmid 2023
Inovio Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Inovio Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Inovio Announces Positive Preliminary Results From Second Cohort Of Phase 1/2 Trial With Ino-3107 For The Treatment Of Recurrent Respiratory Papillomatosis